0.8226
price down icon3.22%   -0.0274
 
loading
Precedente Chiudi:
$0.85
Aprire:
$0.8245
Volume 24 ore:
122.40K
Relative Volume:
0.27
Capitalizzazione di mercato:
$7.09M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+11.31%
1M Prestazione:
-48.07%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
Value
$0.8007
$0.85
Intervallo di 1 settimana:
Value
$0.67
$0.86
Portata 52W:
Value
$0.647
$2.75

Metavia Inc Stock (MTVA) Company Profile

Name
Nome
Metavia Inc
Name
Telefono
(857) 702-9600
Name
Indirizzo
545 CONCORD AVENUE, CAMBRIDGE
Name
Dipendente
8
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
MTVA's Discussions on Twitter

Confronta MTVA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
MTVA
Metavia Inc
0.8226 7.09M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Metavia Inc Stock (MTVA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-30 Iniziato H.C. Wainwright Buy

Metavia Inc Borsa (MTVA) Ultime notizie

pulisher
Apr 24, 2025

MetaVia’s Promising Clinical Trial Results and Future Prospects Drive Buy Rating - TipRanks

Apr 24, 2025
pulisher
Apr 23, 2025

MetaVia’s DA-1241 shows promise in Phase 2a MASH trial By Investing.com - Investing.com South Africa

Apr 23, 2025
pulisher
Apr 23, 2025

Copper Miner Rallies as Takeover Buzz Sparks Investor Optimism - The Globe and Mail

Apr 23, 2025
pulisher
Apr 23, 2025

MetaVia’s DA-1241 shows promise in Phase 2a MASH trial - Investing.com

Apr 23, 2025
pulisher
Apr 23, 2025

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 - PR Newswire

Apr 23, 2025
pulisher
Apr 22, 2025

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors - insights.citeline.com

Apr 22, 2025
pulisher
Apr 22, 2025

MetaVia reports promising obesity drug trial results By Investing.com - Investing.com South Africa

Apr 22, 2025
pulisher
Apr 22, 2025

How will MetaVia Inc’s (MTVA) earnings compare to estimates this quarter? - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

RIVN’s Q2 earnings predictions: What the experts say - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

Can Newell Brands Inc (NWL) meet market expectations this quarter? - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

MetaVia Reports Positive Phase 1 Trial Results - TipRanks

Apr 22, 2025
pulisher
Apr 22, 2025

MetaVia (MTVA) Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726 - StreetInsider

Apr 22, 2025
pulisher
Apr 22, 2025

MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential - marketscreener.com

Apr 22, 2025
pulisher
Apr 22, 2025

MetaVia's New GLP-1 Drug Achieves 6.3% Weight Loss in Just 26 Days: Phase 1 Trial Reveals Promising Safety Profile - Stock Titan

Apr 22, 2025
pulisher
Apr 21, 2025

Stock Market Recap: MetaVia Inc (MTVA) Concludes at 0.74, a 0.64 Surge/Decline - DWinneX

Apr 21, 2025
pulisher
Apr 19, 2025

MetaVia’s (MTVA) Buy Rating Reiterated at HC Wainwright - Defense World

Apr 19, 2025
pulisher
Apr 18, 2025

MTVA stock touches 52-week low at $0.7 amid sharp annual decline - Investing.com Canada

Apr 18, 2025
pulisher
Apr 17, 2025

MTVA stock touches 52-week low at $0.7 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 16, 2025

MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%… - Zacks Small Cap Research

Apr 16, 2025
pulisher
Apr 16, 2025

Korean Dental Association forms election planning team to enhance public oral healthCHOSUNBIZ - Chosunbiz

Apr 16, 2025
pulisher
Apr 16, 2025

MetaVia’s obesity drug cuts body weight by 6.3% in 26 days in phase 1 - koreabiomed.com

Apr 16, 2025
pulisher
Apr 16, 2025

MetaVia reports positive obesity drug trial results By Investing.com - Investing.com Canada

Apr 16, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.39% - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

United States shares lower at close of trade; Dow Jones Industrial Average down 0.39% - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia Reports 'Positive' Results for Obesity Treatment in Part 2 of Phase 1 Trial - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News

Apr 15, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Smart Shirt Might Predict Heart Problems - WFMZ.com

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia reports positive obesity drug trial results - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia Announces Positive Phase 1 Trial Results - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

Metavia Announces Positive Top-Line Data From The 4-Week Phase 1 Mad Trial Of Da-1726 - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia announces ‘positive’ results from Part 2 of Phase 1 trial of DA-1726 - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia (MTVA) Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726 - StreetInsider

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia's New GLP-1 Drug Achieves 6.3% Weight Loss Without TitrationGame-Changing Trial Results - Stock Titan

Apr 15, 2025
pulisher
Apr 14, 2025

Home-Delivered Medical Meals Could Prevent Millions Of Hospitalizations A Year - WFMZ.com

Apr 14, 2025
pulisher
Apr 14, 2025

SCHD ETF News, 4/14/2025 - The Globe and Mail

Apr 14, 2025
pulisher
Mar 31, 2025

MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon… - Yahoo Finance

Mar 31, 2025
pulisher
Mar 24, 2025

MetaVia Inc. Reports Progress in Cardiometabolic Drug Development - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy - TradingView

Mar 24, 2025
pulisher
Mar 24, 2025

FY2029 Earnings Forecast for MetaVia Issued By HC Wainwright - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

HC Wainwright Reaffirms “Buy” Rating for MetaVia (NASDAQ:MTVA) - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Positive Outlook on MetaVia’s Promising Pipeline and Strategic Growth Despite Market Challenges - TipRanks

Mar 22, 2025
pulisher
Mar 22, 2025

MetaVia Inc (MTVA) Reports Q4 EPS of -0.59, Revenue at $0 Millio - GuruFocus

Mar 22, 2025
pulisher
Mar 20, 2025

MetaVia Inc. (MTVA) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

Bank of England leaves benchmark interest rate unchanged at 4.50% with inflation still high - 69News WFMZ-TV

Mar 20, 2025
pulisher
Mar 20, 2025

Stock market today: Wall Street gives back some gains after the Fed extends interest rate pause - WFMZ.com

Mar 20, 2025
pulisher
Mar 20, 2025

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update - PR Newswire

Mar 20, 2025
pulisher
Mar 20, 2025

Tonsil Removal Helps Kids With Snoring/Sleep Apnea - 69News WFMZ-TV

Mar 20, 2025
pulisher
Mar 20, 2025

New Clot-Busting Drug Quicker And As Effective In Treating Stroke - 69News WFMZ-TV

Mar 20, 2025

Metavia Inc Azioni (MTVA) Dati Finanziari

Non sono disponibili dati finanziari per Metavia Inc (MTVA). Controlla altri titoli per ulteriori informazioni.

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Capitalizzazione:     |  Volume (24 ore):